Reverie Labs
Edit info- Founded: 2017
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: Clin0
- Therapy area: Oncology
- Drug types: ONC
- Lead product: RVL-101
- Funding: $25M A Feb 2021
reverielabs.com linkedin.com job board
Business:
Brain-penetrant cancer therapies
Drug notes:
RVL-102 RD oncology; RVL-103 RD oncology; undisclosed programs RD undisclosed
About:
Reverie Labs is pioneering technology to develop next-generation cancer therapies. Computational chemistry and machine learning provide new tools for drug discovery. Reverie is using these methods to develop small molecule kinase inhibitors to treat cancer. The process involves prediction of important molecular properties for on-target drug binding, screening millions of compounds in their virtual libraries for hit identification and molecular dynamics to understand the energetics of bound ligands to their protein targets. Reverie also uses algorithmic molecular generation to ensure selective molecules are synthesizable, stable and tissue-penetrant. With this approach, Reverie will advance a pipeline of tissue-penetrant kinase inhibitors for oncology targets.
Jobs:
News:
Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions - PR Newswire
googlenews
Feb 28, 2024
Funding-related
external-link
Ginkgo Bioworks scales up again with M&A frenzy - pharmaphorum
googlenews
Feb 29, 2024
Science/business updates
external-link
Ginkgo-a-go-go! Bioworks company forges 3 acquisition deals - Fierce Biotech
googlenews
Feb 28, 2024
Science/business updates
external-link
Ginkgo Acquires Key Assets Of Reverie Labs - Contract Pharma
googlenews
Feb 28, 2024
Funding-related
external-link
Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer ...
crunchbase
Mar 5, 2024
Science/business updates
external-link
Reverie Labs uses new machine learning algorithms to fix drug development bottlenecks - TechCrunch
googlenews
Mar 16, 2018
Science/business updates
external-link
This RDV-Backed Startup Uses AI to Speed up the Design of New Drugs - The Business Journals
googlenews
Jun 30, 2017
Science/business updates
external-link
Acquiring Reverie Labs Platform to Enhance AI-Driven Drug Discovery Capabilities for Customer Programs - Ginkgo Bioworks
linkedin
Dec 19, 2024
Science/business updates
external-link
Reverie Labs raises 25M - Harvard School of Engineering and Applied Sciences
googlenews
Feb 9, 2021
Funding-related
external-link
A Virtual Drug Discovery Company—With No Lab Of Its Own—Partners With Roche To Fight Cancers In The Brain - Forbes
googlenews
Aug 25, 2020
Science/business updates
external-link
Reverie Labs: Scaling Drug Development with Containerized Machine Learning - AWS Blog
googlenews
Mar 6, 2020
Science/business updates
external-link
Reverie Labs uses new machine learning algorithms to fix drug development bottlenecks
crunchbase
Mar 16, 2018
Science/business updates
external-link
Reverie Labs Raises $25M Series A Round to Broaden Impact of its Computational Kinase Drug Discovery Platform
crunchbase
Feb 5, 2021
Funding-related
external-link
Adaptive Biotechnologies, Genentech announce FDA acceptance of investigational new drug application - The Science Board
googlenews
May 9, 2023
Science/business updates
external-link
Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs - PR Newswire
googlenews
Feb 28, 2024
Science/business updates
external-link
Reverie Labs Enters Multi-target Collaboration Agreement with Roche
crunchbase
Jul 8, 2020
Science/business updates
external-link
Ginkgo Bioworks acquires Reverie Labs AI assets By Investing.com
crunchbase
Mar 5, 2024
Funding-related
external-link
Ginkgo Bioworks acquires 3 companies - LabPulse
googlenews
Feb 29, 2024
Science/business updates
external-link
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com